Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 03/15/18

Minkyung (Min) Song, Ph.D.

Min Song, Program Director

Program Director

Dr. Minkyung Song fosters, manages, oversees and analyzes the NCI portfolio on multidisciplinary, translational and clinical research grants and cooperative agreements for:

  • Clinical trials of chemotherapy, immunotherapy, cellular therapy, gene therapy, radiation therapy, surgery, or their combinations, and associated correlative studies
  • Discovery and development of new or improved anti-tumor agents
  • Development and validation of clinical tools for monitoring responses to therapies, acquired resistance, adaptive immunity and recurrence of cancer.

Dr. Song serves for the Cancer Moonshot Implementation Team for Blue Ribbon Panel Recommendation on the "Cancer Immunotherapy Translational Science Network." She currently serves as the NCI Program Contact for several funding opportunity announcements (FOAs), including three Cancer Moonshot FOAs and an FOA for extramural-intramural collaborative research at the NIH Clinical Center. She has participated in several trans-NIH activities, including the Adverse Drug Reactions Working Group, the Pharmacogenomics Research Network, the Rigor and Reproducibility Focus Group and the Translational Research Interest Group.

Dr. Song has received various Awards and Certificates, including NIH Merit Awards, the NIH Director's Award, and a Certificate for completing the NIH Senior Leadership Program.

Dr. Song received her Ph.D. degree in Biochemistry and Molecular Biology from the University of Minnesota Medical School in 1983. She was a Visiting Post-Doctoral Fellow and a Senior Staff Fellow in the NIH Intramural Research Program for more than 5 years. Then, Dr. Song was an Interdisciplinary Regulatory Review Scientist in the Food and Drug Administration for 9 years prior to joining DCTD in 1997 as a Program Director.

About the Branch Chief

Jeffrey A. Moscow, MD Jeffrey A. Moscow, MD, joined the Investigational Drug Branch (IDB) in 2014 after serving part time since 2012, and was appointed Branch Chief in 2018. He is a graduate of Harvard University and the Geisel School of Medicine at Dartmouth. Dr. Moscow completed his pediatric residency at the University of Texas Southwestern in Dallas and a fellowship in pediatric hematology-oncology in the Pediatric Oncology Branch, NCI. More…